Pharma: Page 55
-
National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49565158908/in/album-72157713108522106/.
Vir, GSK push coronavirus antibody drug straight into mid-stage tests
The two companies, chasing rival treatments from Eli Lilly, Regeneron and more, aim to produce their first study results by the end of the year.
By Jonathan Gardner • Aug. 31, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
CanSino said to seek early authorization of coronavirus vaccine
The reported talks between CanSino and several countries highlight the urgency with which governments are operating to secure supply of experimental coronavirus vaccines.
By Jonathan Gardner • Aug. 28, 2020 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Permission granted by BioNTech SE
Moderna's vaccine may have an edge when immunization programs roll out
A rival shot from Pfizer and BioNTech needs to be stored at colder temperatures and doesn't last as long in a refrigerator, which may limit its use.
By Jonathan Gardner • Aug. 26, 2020 -
Moderna says its coronavirus vaccine sparks immune response in older people
An initial look at the vaccine's effects on the elderly shows those in their 70s had similar responses to those under 55, Moderna told a government panel.
By Jonathan Gardner • Aug. 26, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
AstraZeneca's coronavirus antibody drug cocktail begins human tests as rivals slip
The British pharma has started a Phase 1 trial amidst reports that competing programs from Regeneron and Eli Lilly haven't met their projected timelines.
By Ben Fidler • Aug. 25, 2020 -
Permission granted by Novartis
Novartis set to take on Roche as FDA clears first at-home, injectable MS drug
Kesimpta, a new multiple sclerosis drug from Novartis, works the same way as Roche's blockbuster Ocrevus, but patients can take it without leaving home.
By Ben Fidler • Aug. 20, 2020 -
Courtesy of Eli Lilly
Lilly doubles down on Innovent cancer drug in immunotherapy push
The Indianapolis pharma paid $200 million to gain most of the rights to Tyvyt, a checkpoint blocker that could help it compete with Merck, Roche and others.
By Ben Fidler • Aug. 18, 2020 -
Permission granted by Gilead Sciences
Gilead expands Tango alliance, continuing a busy year of cancer deals
A $145 million payment to broaden a partnership with Tango Therapeutics is the latest in a series of deals Gilead has made to grow its oncology business.
By Jonathan Gardner • Aug. 18, 2020 -
Courtesy of Sanofi
Sanofi, seeking control of key drug, to buy Principia for $3.7B
The acquisition significantly increases Sanofi's bet on Principia's chief asset, an experimental drug for multiple sclerosis now in late-stage testing.
By Ned Pagliarulo • Aug. 17, 2020 -
Roche wins FDA approval for first self-administered biologic for rare eye disease
Enspryng is the second drug OK'd in three months for an autoimmune disorder that causes blindness and impaired mobility, but it's the only one that patients can take at home.
By Jonathan Gardner • Aug. 17, 2020 -
Europe, trailing US, UK, reaches first coronavirus vaccine deal
Both the U.S. and U.K. have aggressively signed preorder deals with vaccine developers. An agreement with AstraZeneca is the EU's first.
By Ned Pagliarulo • Aug. 14, 2020 -
Bristol Myers pledges to spend $300M on addressing racial, health disparities
The drugmaker aims to double Black and Latinx representation in its executive ranks, among other commitments.
By Kristin Jensen • Aug. 12, 2020 -
Moderna gets $1.5B from US for coronavirus vaccine supply
The U.S. has already invested heavily in Moderna's shot, having previously committed $1 billion to fund clinical trials and manufacturing scale-up.
By Ned Pagliarulo • Aug. 11, 2020 -
First oral drug for spinal muscular atrophy approved by FDA
Roche priced Evrysdi below the cost of competing treatments from Novartis and Biogen, but the drug's list price still tops $100,000 for many patients.
By Ben Fidler • Aug. 7, 2020 -
Permission granted by Gilead Sciences
Pfizer to help Gilead produce COVID-19 drug remdesivir
With supplies of the in-demand drug tight, Gilead has enlisted Pfizer, along with companies across the globe, to churn out millions of treatment courses.
By Ned Pagliarulo • Aug. 7, 2020 -
GSK wins US approval for first-of-its-kind blood cancer drug
Blenrep is the first multiple myeloma therapy cleared by the FDA that targets BCMA, a protein that's the focus of high-profile drug development efforts.
By Ned Pagliarulo • Aug. 6, 2020 -
Bristol Myers, Pfizer fend off a key challenge to their top-selling heart drug
A district court ruling likely ensures that the companies' blood thinner Eliquis won't face generic competition until at least 2026.
By Ben Fidler • Aug. 6, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
Big pharma alliance recruits first patients for unusual COVID-19 study
The trial is testing whether drugs from Amgen, Takeda and AbbVie can combat the life-threatening immune overreaction some COVID-19 patients experience.
By Jacob Bell • Aug. 3, 2020 -
Bausch Health to pay $45M to settle US charges over Valeant-era accounting
The agreement comes four years after an accounting scandal led to the unraveling of then-Valeant's image as a new breed of drugmaker.
By Ned Pagliarulo • Aug. 3, 2020 -
Courtesy of Eli Lilly
Lilly to test COVID-19 antibody drug in unorthodox nursing home study
Seeking fast answers in a pandemic, Lilly will use mobile RVs to set up infusion clinics at assisted living facilities, which have become COVID-19 hot spots.
By Ben Fidler • Aug. 3, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
Vaccine sales driven down by pandemic's effects on doctor visits
Pfizer, Sanofi, GSK and Merck each reported lower vaccine sales as stay-at-home orders kept people from their regular vaccinations.
By Jacob Bell • July 31, 2020 -
US promises $2.1B to Sanofi, GSK in latest coronavirus vaccine deal
The contract is the largest yet from the Trump administration's Operation Warp Speed, although Sanofi and GSK have yet to begin clinical testing of their shot.
By Ned Pagliarulo • July 31, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49565158908/in/album-72157713108522106/.
AstraZeneca signals it won't wait for US data to seek clearance of coronavirus vaccine
The British drugmaker indicated on a conference call that data from trials already underway in the U.K., Brazil and South Africa will be sufficient to ask regulators to approve the vaccine.
By Jonathan Gardner • July 30, 2020 -
National Institute of Allergy and Infectious Disease. (2020). "Novel Coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49565158853/.
J&J, beginning first human trial, aims for a 1-shot coronavirus vaccine
Preclinical data published Thursday suggest one dose of J&J's vaccine could protect against coronavirus disease, but that goal has proved difficult for drugmakers so far.
By Ben Fidler • July 30, 2020 -
Bristol Myers resubmits cancer cell therapy, lifting investors' chance at payout
A surprise refusal by the FDA in May to review Bristol Myers' application put at risk a conditional payment promised as part of the pharma's Celgene deal.
By Ben Fidler • July 29, 2020
Previous
